What is Embark Veterinary?
Based in Boston, Massachusetts, Embark Veterinary operates at the intersection of biotechnology and consumer pet care. The company provides comprehensive DNA testing services for dogs, offering owners detailed insights into breed composition, physical traits, and potential health predispositions. Beyond individual consumer utility, the company leverages its expansive genetic database to fuel scientific research, aiming to improve the longevity and quality of life for dogs globally.
The firm's market position is defined by its dual-sided business model: a direct-to-consumer testing service and a research-oriented data platform. By synthesizing complex genomic data into actionable health information, Embark Veterinary has established itself as a critical player in the burgeoning pet health-tech ecosystem, effectively bridging the gap between veterinary science and accessible pet ownership tools.
How much funding has Embark Veterinary raised?
Embark Veterinary has raised a total of $91.3M across 4 funding rounds:
Other Financing Round
$1.8M
Other Financing Round
$4.5M
Series A
$10M
Series B
$75M
Other Financing Round (2016): $1.8M with participation from AGO Partners, Slow Ventures, and Fabrice Grinda
Other Financing Round (2017): $4.5M led by Section 32, SV Angel, Anne Wojcicki, and Founder Collective
Series A (2019): $10M supported by Freestyle Capital, F-Prime Capital Partners, Section 32, Anne Wojciciki, Third Kind Venture Capital, Slow Ventures, and FJ Labs
Series B (2021): $75M featuring SoftBank Group, SV Angel, F-Prime Capital Partners, Freestyle, Third Kind Venture Capital, and Slow Ventures
Key Investors in Embark Veterinary
SoftBank Group
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, smart robotics, IoT, and clean energy technologies.
F-Prime Capital Partners
Founded in 2002, F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
SV Angel
SV Angel is a long-term investment firm dedicated to supporting founders in creating impactful businesses by providing essential resources, strategic insights, and a vast network.
What's next for Embark Veterinary?
With the support of its latest strategic investment, Embark Veterinary is well-positioned to accelerate its research initiatives and expand its market reach. The company is expected to focus on enhancing its diagnostic capabilities and deepening its integration within the veterinary clinical workflow. As the pet health industry continues to prioritize preventative care, Embark's ability to leverage its massive genetic repository will likely serve as a primary driver for future growth and industry partnerships.
The strategic focus moving forward will likely involve scaling operations to meet increasing demand while maintaining the high standards of accuracy that have defined its brand. By continuing to attract sophisticated capital, the company is prepared to navigate the complexities of the biotech landscape and maintain its competitive edge in the evolving pet wellness market.
